Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.7K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.7K
Drug Discovery: Overview01:26

Drug Discovery: Overview

11.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.9K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.4K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.5K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

3
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
3

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

At the nucleus of cancer: how the nuclear envelope controls tumor progression.

MedComm·2025
Same author

TP53 gene status can promote sensitivity and resistance to chemotherapeutic drugs and small molecule signal transduction inhibitors.

Advances in biological regulation·2025
Same author

The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH.

Advances in biological regulation·2024
Same author

Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL).

International journal of molecular sciences·2023
Same author

Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies.

Advances in biological regulation·2022
Same author

Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.

Cells·2022

Related Experiment Video

Updated: Feb 13, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

17.7K

Drug discovery targeting the mTOR pathway.

Alberto M Martelli1, Francesca Buontempo2, James A McCubrey3

  • 1Department of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy alberto.martelli@unibo.it mccubreyj@ecu.edu.

Clinical Science (London, England : 1979)
|March 11, 2018
PubMed
Summary

Mechanistic target of rapamycin (mTOR) signaling drives cancer progression, but current mTOR inhibitors show limited efficacy. Further research is needed to understand their therapeutic potential and overcome resistance mechanisms in cancer treatment.

Keywords:
cancer therapymechanistic target of rapamycinphosphoinositide 3-kinaseprotein kinase Brapalogs

More Related Videos

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.3K
Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
07:25

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids

Published on: August 18, 2023

2.6K

Related Experiment Videos

Last Updated: Feb 13, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

17.7K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.3K
Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
07:25

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids

Published on: August 18, 2023

2.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Mechanistic target of rapamycin (mTOR) is crucial for cellular processes and is deregulated in cancer.
  • mTOR signaling pathways (mTORC1 and mTORC2) control cancer cell proliferation, survival, and metastasis.
  • mTOR is a validated therapeutic target in oncology due to its role in cancer development.

Purpose of the Study:

  • To review the current landscape of mTOR inhibitors for cancer therapy.
  • To summarize preclinical and clinical findings on mTOR-targeted drugs.
  • To provide insights into the efficacy and limitations of mTOR inhibitors in cancer treatment.

Main Methods:

  • Literature review of preclinical studies on mTOR inhibitors.
  • Analysis of clinical trial data for mTOR-targeted therapies.
  • Synthesis of current knowledge on mTOR pathway in cancer.

Main Results:

  • Rapamycin and its analogs (rapalogs) demonstrated limited clinical efficacy despite promising preclinical data.
  • Novel mTOR inhibitors with enhanced potency show weak antitumor activity in emerging clinical data.
  • Understanding mTOR inhibitor efficacy and failure is crucial for developing effective cancer treatments.

Conclusions:

  • mTOR inhibitors represent a promising therapeutic strategy for cancer, but clinical success has been limited.
  • Further investigation into the mechanisms of resistance and efficacy of mTOR inhibitors is essential.
  • Optimizing mTOR-targeted therapies requires a deeper understanding of their clinical performance and limitations.